RXRX
HEALTHCARERecursion Pharmaceuticals Inc - Class A
$3.43+0.06 (+1.78%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RXRX Today?
No stock-specific AI insight has been generated for RXRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.80$7.18
$3.43
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume17.7M
Avg Volume (10D)—
Shares Outstanding524.7M
RXRX News
21 articles- 3 Stocks Poised to Disrupt the Healthcare Market by 2030Motley Fool·May 8, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right NowYahoo Finance·May 7, 2026
- Recursion (RXRX) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Recursion Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Recursion Reports First Quarter Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?Yahoo Finance·May 3, 2026
- What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny StockYahoo Finance·May 3, 2026
- Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key FactsYahoo Finance·May 1, 2026
- Recursion Announces Board TransitionYahoo Finance·Apr 30, 2026
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should KnowYahoo Finance·Apr 29, 2026
- Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6Yahoo Finance·Apr 29, 2026
- [Latest] Global Generative AI in Chemical Market Size/Share Worth USD 12.84 Billion by 2035 at a 24.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Apr 28, 2026
- Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 PrioritiesYahoo Finance·Apr 26, 2026
- Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss ForecastYahoo Finance·Apr 25, 2026
- A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain AttentionYahoo Finance·Apr 24, 2026
- Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketYahoo Finance·Apr 23, 2026
- Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working?Yahoo Finance·Apr 22, 2026
- Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline PartnershipYahoo Finance·Apr 19, 2026
- Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformGlobeNewswire Inc.·Mar 31, 2026
All 21 articles loaded
Price Data
Open$3.19
Previous Close$3.37
Day High$3.37
Day Low$3.14
52 Week High$7.18
52 Week Low$2.80
52-Week Range
$2.80$7.18
$3.43
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.16
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume17.7M
Avg Volume (10D)—
Shares Outstanding524.7M
About Recursion Pharmaceuticals Inc - Class A
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—